EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Direction of Modern Therapies in Waldenström Macroglobulinaemia

Stephen Blackmore, Sherine Elsawa, Omid Tavana iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70987 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Stephen Blackmore und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science and Agriculture, Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, New Hampshir…. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Waldenström macroglobulinaemia (WM) is a rare lymphoplasmacytic disease that is hallmarked by B‐cell infiltration of the bone marrow, an overexpression of IgM class antibodies and an activating mutation of MYD88 (L265P). The therapeutic options for WM patients include a combination of Rituximab (anti‐CD20 monoclonal antibody) and chemotherapy, with newer treatments like proteasomal inhibitors and Bruton's Tyrosine Kinase (BTK) inhibitors showing high levels of success both as monotherapy and in combinations. To date, WM remains incurable. Understanding the basic physiology of WM and creating new and improved pre‐clinical models which better reflect the true physiology of WM will allow for the identification of novel therapeutic vulnerabilities and the ability to test these next generation therapies, both in a tumour intrinsic and extrinsic manner. In this review, we aim to provide a comprehensive summary of WM, focusing on the genetic mutations and signalling pathways driving disease progression. In addition, we highlight the current therapeutics and emerging clinical trials to provide novel insights to drive deep and durable responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaHumansMutationMyeloid Differentiation Factor 88Signal TransductionAnimalsAgammaglobulinaemia Tyrosine KinaseRituximab

Stichwörter der Autor:innen

Waldenström macroglobulinaemiacancer signallingmodern therapies

Substanzen

Myeloid Differentiation Factor 88Agammaglobulinaemia Tyrosine KinaseRituximab

Autor:innen und Institutionen

  • College of Life Science and Agriculture, Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, New Hampshire, USA.
  • Bioscience, Haematology R&D, AstraZeneca, Waltham, Massachusetts, USA.

ORCID-Profile: Omid Tavana

Zitieren

APA

Blackmore, S., Elsawa, S., & Tavana, O. (2025). The Direction of Modern Therapies in Waldenström Macroglobulinaemia. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70987

Vancouver

Blackmore S, Elsawa S, Tavana O. The Direction of Modern Therapies in Waldenström Macroglobulinaemia. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70987

BibTeX
@article{Blackmore2025,
  author = {Blackmore, Stephen and Elsawa, Sherine and Tavana, Omid},
  title = {The Direction of Modern Therapies in Waldenström Macroglobulinaemia},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70987}
}
Kostenlos starten →